Advertisement

Cholinergic and peptidergic systems in PSP

  • F. Javoy-Agid
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 42)

Summary

PSP is associated with a widespread cholinergic deficit likely corresponding to a loss in cholinergic neurons. The cholinergic damage dramatically affects the basal ganglia and specific cell groups of the mes-encephalon and pons. This provides an anatomically defined basis for motor and supranuclear oculomotor syndromes characteristic of PSP.

Unlike Alzheimer’s disease and Parkinson’s disease with dementia, the disease is not associated with a marked cholinergic deficiency in the cerebral cortex.

Various peptides are present at normal concentrations in extrapyramidal and limbic subcortical areas in brains of patients with PSP. Of particular interest, is somatostatin, the levels of which are subnormal in cerebral cortex of patients with dementia of Alzheimer’ or Parkinson’s disease type.

Keywords

Substantia Nigra Cholinergic Neuron Progressive Supranuclear Palsy ChAT Activity Cholinergic Innervation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C, Hauw JJ, Baron JC, Scatton B (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 191–206.Google Scholar
  2. Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworth, pp 166-230.Google Scholar
  3. Baron JC, Mazière B, Loc’h C, Sgouropoulos P, Bonnet AM, Agid Y (1985) Progressive supranuclear palsy. Loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet i: 1163–1164.CrossRefGoogle Scholar
  4. Blumenthal H, Miller C (1969) Motor nuclear involvement in progressive supranuclear palsy. Arch Neurol 20: 362–367.PubMedCrossRefGoogle Scholar
  5. Brandel JP, Hirsch EC, Javoy-Agid F (1990) Compartmental ordering of cholinergic innervation in the mediodorsal nucleus of the thalamus in human brain. Brain Res 515: 117–125.PubMedCrossRefGoogle Scholar
  6. Brandel JP, Hirsch EC, Malessa S, Duyckaerts C, Cervera P, Agid Y (1991) Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy. Neuroscience 41: 25–31.PubMedCrossRefGoogle Scholar
  7. Büttner-Ennever JA, Büttner U (1978) A cell group associated with vertical eye movements in the rostral mesencephalic reticular formation of the monkey. Brain Res 151: 31–47.PubMedCrossRefGoogle Scholar
  8. Büttner-Ennever JA, Büttner U (1982) Vertical gaze paralysis and the rostral interstitial nucleus of the medial longitudinal fasciculus. Brain 105: 125–149.PubMedCrossRefGoogle Scholar
  9. Cambier J, Masson M, Viader F, Limodin J, Strube A (1985) Le syndrome frontal de la paralysie supranucléaire progressive. Rev Neurol (Paris) 141: 528–536.Google Scholar
  10. Carpenter MB, Sutin J (1983) Human neuroanatomy. Williams & Wilkins, Baltimore, p 428.Google Scholar
  11. Carpenter MB, Harbison JW, Peter P (1970) Accessory oculomotor nuclei in the monkey: projections and effects of discrete lesions. J Comp Neurol 140: 131–154.PubMedCrossRefGoogle Scholar
  12. Chau TT, Izazola-Conde C, Dewey WL (1982) Evidence for the existence of peptide and nonpeptide morphine-like materials in mouse brain: effect of an analgesic intracerebroventricular dose of acetylcholine on their levels. J Pharmacol Exp Ther 222: 612–616.PubMedGoogle Scholar
  13. Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F (1988) Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson’s disease. Arch Neurol 45: 1194–1199.PubMedCrossRefGoogle Scholar
  14. Edley SM, Graybiel AM (1983) The afferent and efferent connections of the feline nucleus tegmenti pedunculopontinus, pars compacta. J Comp Neurol 217: 187–215.PubMedCrossRefGoogle Scholar
  15. Epelbaum J, Ruberg M, Moyse E, Javoy-Agid F, Dubois B, Agid Y (1983) Somatostatin and dementia in Parkinson’s disease. Brain Res 278: 376–379.PubMedCrossRefGoogle Scholar
  16. Epelbaum J, Javoy-Agid F, Hirsch EC, Hauw JJ, Kordon C, Krantic S, Agid Y (1987) Brain somatostatin concentrations do not decrease in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 50: 1526–1528.PubMedCrossRefGoogle Scholar
  17. Epelbaum J, Javoy-Agid, Enjalbert A, Krantic S, Kordon C, Agid Y (1988) Somatostatin concentrations and binding sites in human frontal cortex are differently affected in Parkinson’s disease associated with dementia and in progressive supranuclear palsy. J Neurol Sci 87: 167–174.PubMedCrossRefGoogle Scholar
  18. Fukishima-Kudo J, Fukushima K, Tashiro K (1987) Rigidity and dorsiflexion of the neck in progressive supranuclear palsy and the interstitial nucleus of Cajal. J Neurol Neurosurg Psychiatry 50: 1197–1203.CrossRefGoogle Scholar
  19. Girault JA, Raisman-Vozari R, Agid Y, Greengard P (1989) Striatal phosphoproteins in Parkinson’s disease and progressive supranuclear palsy. Proc Natl Acad Sci USA 86: 2493–2497.PubMedCrossRefGoogle Scholar
  20. Hallanger AE, Wainer BH (1988) Ascending projections from the pedunculontine tegmental nucleus and the adjacent mesopontine tegmentum in the rat. J Comp Neurol 274: 483–515.PubMedCrossRefGoogle Scholar
  21. Hanson GR, Alphs L, Wolf W, Levine R, Lovenberg W (1981) Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems. J Pharmacol Exp Ther 218: 568–574.PubMedGoogle Scholar
  22. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the peduncolupontine tegmental nucleus in Parkinson’s disease and in progressive supranuclear palsy. Proc Natl Acad Sci 84: 5976–5980.PubMedCrossRefGoogle Scholar
  23. Hirsch EC, Graybiel AM, Hersh LB, Duyckaerts C, Agid Y (1989) Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acety-ltransferase in the human striatum. Neurosci Lett 96: 145–150.PubMedCrossRefGoogle Scholar
  24. Hirsch EC, Graybiel AM, Agid Y (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature: 345-348.Google Scholar
  25. Hong JS, Yang HYT, Fratta W, Costa E (1978) Rat striatal methionine-enkephalin content after chronic treatment with cataleptogenic and non cataleptogenic antis-chizophrenic drugs. J Pharmacol Exp Ther 205: 141–147.PubMedGoogle Scholar
  26. Jellinger K, Riederer P, Tomonga M (1980) Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm [Suppl] 16: 111–128.Google Scholar
  27. Jellinger K (1988) The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 51: 540–543.PubMedCrossRefGoogle Scholar
  28. Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y (1991) Mesen-cephalic cholinergic nuclei in Progressive Supranuclear Palsy. Neurology 41: 25–30.PubMedCrossRefGoogle Scholar
  29. Kish SJ, Chang MS, Mirchandani, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia and brain neurotransmitter markers. Ann Neurol 18: 530–536.PubMedCrossRefGoogle Scholar
  30. Lehéricy S, Hirsch E, Cervera P, Hersh LB, Hauw JJ, Ruberg M, Agid Y (1989) Selective loss of cholinergic neurones in the ventral striatum of patients with Alzheimer’s disease. Proc Natl Acad Sci USA 86: 8580–8586.PubMedCrossRefGoogle Scholar
  31. Malessa S, Hirsch EC, Cervera P, Javoy-Agid F, Duyckaerts C, Hauw JJ, Agid Y (1991) Progressive supranuclear palsy: loss of choline acetyltransferase-like-immunoreactive neurons in the pontine reticular formation. Neurology 41:1593–1597.PubMedCrossRefGoogle Scholar
  32. Mesulam MM, Mufson EJ, Levey AL, Wainer BH (1984) Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltranferase immunohistochemistry and acetylcholinesterase histochemistry. Neuroscience 12: 669–686.PubMedCrossRefGoogle Scholar
  33. Monfort JC, Javoy-Agid F, Hauw JJ, Dubois B, Agid Y (1985) Brain glutamate decarboxylase in Parkinson’s disease: an index of premortem seventy. Brain 108: 301–313.PubMedCrossRefGoogle Scholar
  34. Oblin A, Zivcovic B, Bartholini G (1984) Involvement of the D2 dopamine receptor in the neuroleptic-induced decrease in nigral substance. Eur J Pharmacol 105: 175–177.PubMedCrossRefGoogle Scholar
  35. Pierot L, Desnos C, Blin J, Raisman R, Sherman D, Javoy-Agid F, Ruberg M, Agid Y (1988) D1 and D2 dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 86: 291–306.PubMedCrossRefGoogle Scholar
  36. Pierrot-Deseilligny C, Turell E, Penet C, Lebrigand D, Pillon B, Chain F, Agid Y (1989) Increased wave P 300 latency in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 52: 656–658.PubMedCrossRefGoogle Scholar
  37. Pierrot-Deseilligny C, Rivaud S, Pillon B, Agid Y (1989) Lateral visually-guided saccades in progressive supranuclear palsy. Brain 112: 471–487.PubMedCrossRefGoogle Scholar
  38. Pillon B, Dubois B, Lhermitte F, Agid Y (1986) Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 36: 1179–1185.PubMedCrossRefGoogle Scholar
  39. Raisman-Vozari R, Girault JA, Feurstein C, Jenner P, Marsden CD, Agid Y (1990) Lack of changes in striatal DARP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man. Brain Res 507: 45–50.PubMedCrossRefGoogle Scholar
  40. Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, Lheureux R, Hauw JJ, Duyckaerts C, Gray F, Morel-Maroger A, Rascol A, Serdaru M, Agid Y (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18: 523–529.PubMedCrossRefGoogle Scholar
  41. Ruberg M, Villageois A, Bonnet AM, Pillon B, Rieger F, Agid Y (1987) Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. J Neurol Neurosurg Psychiatry 50: 538–543.PubMedCrossRefGoogle Scholar
  42. Ruberg M, Agid Y (1988) Dementia in Parkinson’s disease. In: Iversen LL, Iversen SD, Snyder SH (eds) Psychopharmacology of the aging nervous system. Plenum Press, New York, pp 157–206 (Handbook of psychopharmacology, vol 20).Google Scholar
  43. Ruberg M, Hirsch E, Javoy-Agid F (1992) Neurochemistry. In: Litvan I, Agid Y (eds) Progressive supranuclear palsy, vol 5. Oxford University Press, New York, pp 89–109.Google Scholar
  44. Steele JC (1972) Progressive supranuclear palsy. Brain 95: 693–704.PubMedGoogle Scholar
  45. Steele JC, Richardson JC, Olszewski (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy, nuclear dystonia and dementia. Arch Neurol 10: 333–359.PubMedCrossRefGoogle Scholar
  46. Studier JM, Javoy-Agid F, Cesselin F, Legrand JC, Agid Y (1982) CCK-8 immu-noreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients. Brain Res 243: 176–179.CrossRefGoogle Scholar
  47. Tagliavini F, Pilleri G, Gemignani F, Lechi A (1983) Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol (Bed) 61: 157–160.CrossRefGoogle Scholar
  48. Taquet H, Javoy-Agid F, Mauborgne A, Benoliel JJ, Agid Y, Legrand JC, Hamon M, Cesselin F (1987) Brain neuropeptides in progressive supranuclear palsy. Brain Res 411: 178–182.PubMedCrossRefGoogle Scholar
  49. Troost BT, Daroff RB (1977) The ocular motor defects in progressive supranuclear palsy. Ann Neurol 2: 397–403.PubMedCrossRefGoogle Scholar
  50. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ (1988) Reductions in acetylcholine and nicotine binding in several degenerative disease. Arch Neurol 22: 18–25.Google Scholar
  51. Zweig RM, Whitehouse P, Casanova MF, Walker L, William RJ, Price DL (1988) Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 22: 18–25.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • F. Javoy-Agid
    • 1
    • 2
  1. 1.INSERM U 289Hôpital de la SalpêtrièreParisFrance
  2. 2.Laboratoire de Medicine ExperimentaleHôpital de la SalpêtrièreParisFrance

Personalised recommendations